Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 51Fallopian Tube Neoplasms 28Ovarian Neoplasms 23Carcinoma, Non-Small-Cell Lung 22Triple Negative Breast Neoplasms 15Pancreatic Neoplasms 13Breast Neoplasms, Male 11Lung Neoplasms 10Brenner Tumor 10Inflammatory Breast Neoplasms 7Uterine Cervical Neoplasms 5Endometrial Adenocarcinoma 5Adenocarcinoma of Lung 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Melanoma 4Cholangiocarcinoma 4Carcinoma, Ovarian Epithelial 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma Of Esophagus 4Pleural Effusion, Malignant 3Pancreatic Adenocarcinoma 3Neoplasms 3Thymoma 2Neurotoxicity Syndromes 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinosarcoma 2Breast Carcinoma In Situ 2

Interventions

cobimetinib 1atezolizumab 1Taxes 1Paclitaxel 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma, Mucinous × Taxes × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡